Concepedia

Yutao Gong

YG

Statistics

Publications

19

Citations

1.9K

H-Index

16

Active since

2010

Affiliations

United States Food and Drug Administration(Current)

Center for Drug Evaluation and Research

Center for Devices and Radiological Health

National Cancer Institute

University of Pennsylvania

Yutao Gong is an author at United States Food and Drug Administration specializing in oncology, medicine, and cancer immunotherapy.

Publications per year

2010–2021

19

Publications

19

Phase transitions in biogenic amorphous calcium carbonate

Yutao Gong, Christopher E. Killian, Ian C. Olson et al. · Proceedings of the National Academy of Sciences · 2012 · 296 citations · Full text

, , +15

Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non–Small Cell Lung Cancer

Dickran Kazandjian, Yutao Gong, Patricia Keegan et al. · JAMA Oncology · 2019 · 255 citations · Full text

, , +17

FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma

Elaine Chang, Chana Weinstock, Lijun Zhang et al. · Clinical Cancer Research · 2020 · 183 citations · Full text

, , +11

FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1

Preeti Narayan, Sakar Wahby, Jennifer Gao et al. · Clinical Cancer Research · 2020 · 182 citations

, , +17

FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer

Shaily Arora, Sanjeeve Balasubramaniam, Hui Zhang et al. · The Oncologist · 2020 · 182 citations · Full text

, , +14

1–5 of 19